Aranesp (Erythropoiesis Stimulating Protein) - Summary

ARANESP SUMMARY

Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin, that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Aranesp® is a 165-amino acid protein that differs from recombinant human erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant human erythropoietin contains 3 chains¹. The two additional N-glycosylation sites result from amino acid substitutions in the erythropoietin peptide backbone.

Aranesp® is indicated for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.

ARANESP NEWS HIGHLIGHTS

Media Articles Related to Aranesp (Erythropoiesis Stimulating Protein)

FDA Commands Amgen to Change Darbepoetin Alfa (Aranesp) Label
Source: MedPage Today Product Alert [2008.07.31]

FDA approves extended dosing of Aranesp
Source: The Doctors Lounge - Hematology

more>>

Published Studies Related to Aranesp (Erythropoiesis Stimulating Protein)

Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. [2006.05]

Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. [2005.03]

Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. [2001.08]

Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. [1999.11]

Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. [1996.02]

more>>

Clinical Trials Related to Aranesp (Erythropoiesis Stimulating Protein)

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD) [Completed]

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor [Completed]

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation [Completed]

Study of Aranesp to Treat Anemia in Prostate Cancer Patients. [Completed]

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced [Terminated]

more>>